Why the study?
Does bepridil hydrochloride cause serious adverse effects such as QT prolongation and torsade de pointes in patients with atrial fibrillation and flutter?
Does bepridil hydrochloride cause serious adverse effects such as QT prolongation and torsade de pointes in patients with atrial fibrillation and flutter?
Bepridil administration for atrial fibrillation and flutter carries a 4% risk of adverse effects requiring discontinuation, including a 0.9% risk of torsade de pointes, highlighting the need for careful monitoring of QT interval, heart rate, and serum potassium.
No takes yet. Share an insight, caveat, or question.
Bepridil for AF requires QT, heart rate, and potassium monitoring; observational data leaves open randomized safety confirmation.
Yasuda et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: